Skip to main content
. 2018 Mar 14;11:1756284818759930. doi: 10.1177/1756284818759930

Figure 4.

Figure 4.

Fecal calprotectin concentrations in patients with serum adalimumab concentrations of less than 5 mg/liter versus at least 5 mg/liter in all patients (25 versus 86) (A), in patients with ulcerative colitis (UC) (3 versus 17) (B), and in patients with Crohn’s disease (CD) (22 versus 69) (C). Medians and ranges are shown.